ArticleBMC women's health2026
Interest of PD-L1 in the management of triple negative breast cancers in Ivorian patients.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that does not express hormonal receptors and Her2. Its prevalence is high and varies from 30 to 41% in the Ivory Coast. For decades, chemotherapy has remained the only systematic treatment choice; however, the current availability of programmed death-ligand 1 (PD-L1) immunohistochemistry provides benefits for immune checkpoint inhibitors. The purpose of the study aimed to determine the prevalence of PD-L1 and its relationship with specific prognostic features for better survival of TNBC patients in the Ivory Coast.
methodsA 10-month prospective study included 132 patients diagnosed with TNBC. The paraffin blocks were subjected to PD-L1 immunohistochemistry. The Chi-Square Test was used to evaluate the correlations between PD-L1 status and prognostic parameters.
resultsThe mean age at diagnosis was 46.6 ± 12.9 years. 62.9% of the study population were premenopausal. The predominant histological type was invasive ductal carcinoma of no special type (95.5%) at the advanced stage of grade II (59.1%) and III (27.3%). There was an abundant inflammatory stroma (67.4%). 20.5% of TNBC patients were PD-L1 positive. PD-L1 status was significantly associated with the breast imaging-reporting and data system (BIRADS) scoring (p = 0.0362) and Nottingham grade (p = 0.0049). However, there was no association between PD-L1 expression and menopausal status (p = 0.1771), sex (p = 0.3030), inflammatory stroma (p = 0.0803), tumor necrosis (p = 0.0571), and histological type (p = 0.2037).
conclusion20.5% of TNBC patients expressed PD-L1. This study highlights a significant association between PDL-1 expression and the BIRADS scoring and the Nottingham grade. The present study could help to select patients who would be likely to benefit from anti-PD-L1 immunotherapy for better clinical outcomes in the Ivory Coast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.